2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Radiation Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Biological Processes, Immune Mechanism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Infectious Diseases, Viral, Bacterial, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

2723 Treatment patterns and outcomes post-CAR T failure in LBCL: The "what comes next" question

Christina Fullerton, PharmD, BCOP, Matt Bye2, Maneet Kaur, PhD, MPH3, Ahmed Sawas, MD4
1 Flatiron Health, New York, New York, United States
2 Flatiron Health, New York, New York, United States
3 Flatiron Health, New York, New York, United States
4 Flatiron Health, New York, New York, United States

Introduction: Chimeric antigen receptor T-cell therapy (CAR T) has reshaped relapsed/refractory large B-cell lymphoma (LBCL) treatment, offering durable remissions in about 40% of patients (pts). Despite this, over half of pts experience an early or late relapse (ER/LR) requiring an alternative treatment approach. The expansion of novel post-CAR T options, such as bispecific antibodies (bsAbs), antibody-drug conjugates, and targeted combinations, underscores the need to evaluate real-world (rw) treatment selection and outcomes in this salvage setting. We aimed to describe demographics and clinical characteristics, treatment patterns, and clinical outcomes of pts with LBCL receiving a subsequent line of therapy (LoT) post-CAR T within a large, multisite network.

Methods: Using the US-based, EHR-derived deidentified Flatiron Health Research Database, pts with LBCL who were diagnosed on or after January 1, 2011 and received a post-CAR T LoT were included. Demographics and clinical characteristics were described for the overall cohort. Treatment patterns, real-world progression-free survival (rwPFS), and real-world overall survival (rwOS) were stratified by CAR T setting (early [pre-second-line (2L) approval era, before March 31, 2022]: any line, modern [post-2L approval era, after April 1, 2022] 2L, or modern third-line or later [3L+]), CAR T failure type (primary refractory [no response in CAR T line], ER [response in CAR T line and next line <6 months (mo) post-CAR T infusion], and LR [response in CAR T line and next line >6 mo post-CAR T infusion]), and aged ≤65 vs >65 years. Post-CAR T LoT was categorized by therapy class to describe treatment patterns and rwPFS and rwOS. Unadjusted median (med) time-to-event outcomes with 95% confidence intervals were estimated via Kaplan-Meier analysis, indexed to post-CAR T LoT initiation. All outcomes are descriptive in nature and no formal comparisons were made.

Results: Among 2084 pts with LBCL treated with CAR T, 815 received a post-CAR T LoT (median age 66 years, 65% male, 57% ECOG 0-1, 28% unknown ECOG, 31% transformed disease). CAR T was most commonly given in 3L+ (64%) or 2L (32%) setting, with 4% in 1L setting. Majority of early era was 3L CAR T vs modern era was split evenly between 2L and 3L setting. Pts receiving 1L CAR T (n=21) in modern era were excluded from era-based analyses as these were focused on 2L and 3L+ setting. Median follow-up time was 14 mo from CAR T infusion date and 5.8 mo from start of post-CAR T LoT.

Top post-CAR T LoT therapy classes were chemoimmunotherapy (CIT, 26.6%), bsAbs (20.1%), clinical study drug (12.6%), anti-CD19–containing therapy (8.3%), and chemotherapy (8.2%). CIT was more common in younger pts (≤65 vs >65 years: 32.4% vs 21.2%), whereas older pts mostly received bsAbs (16.7% vs 23.3%). By CAR T setting, CIT was most common in the early era (35.1%) compared with bsAbs in the modern era across both 2L (39.3%) and 3L+ (30.5%). The most common therapy by CAR T failure type: CIT in PR (32.0%), BsAbs and CIT in ER (22.0% each), and CIT in LR (26.5%). BsAbs use was broadly consistent across CAR T failure types: PR (18.8%), ER (22.0%), LR (19.4%).

Overall cohort med rwPFS was 3.8 mo (95% CI, 3.5-4.3) and med rwOS was 9.8 mo (95% CI, 8.5-11.7). In unadjusted analyses, med rwPFS was 3.8 mo with CIT and 3.7 mo with bsAbs; med rwOS was 8.9 and 8.8 mo, respectively. Outcomes by CAR T failure type: 2.7 mo and 6.8 mo in PR, 3.9 mo and 11.3 mo in ER, and 6.8 mo and 21.4 mo in LR for med rwPFS and rwOS, respectively. Med rwPFS was comparable across age and CAR T era groups. Modern era 2L CAR T yielded a longer med rwOS 13.4 mo compared with any line in the early era (9.2 mo) or 3L+ in the modern era (7.8 mo). Med rwOS by age aligned with clinical expectations. 

Conclusions: In this rw study of >2000 pts with LBCL treated with CAR T over 9 years, 39% initiated a subsequent LoT. Treatment patterns revealed a clear era shift from predominant CIT use in earlier years to bsAbs in the modern post-CAR T salvage setting. Outcomes remain poor overall, with CAR T failure type of LR demonstrating best prognosis across these groups. Unadjusted outcomes appear similar among CIT and bsAbs cohorts, while sample sizes limited further evaluation of therapy classes. These data capture a paradigm shift in adoption of novel management strategies post-CAR T, with failure timing as a critical prognostic driver.

Christina Fullerton, PharmD, BCOP: Roche - Current equity holder in publicly-traded company; Flatiron Health, Inc. - Research Funding; Flatiron Health, Inc. - Current Employment